Your English writing platform
Discover LudwigExact(3)
First, we modeled overall nonadherence (intermediate adherence and discontinued groups combined) compared with full adherence.
Experiencing "a lot" of adverse effects, trouble remembering to take pills, and age <45 years were also risk factors for nonadherence in a model combining the intermediate adherence and <span class="lh">discontinued groups compared with full adherence (data not shown).
Both the continuing and discontinued groups revealed significant reduction in number of yearly hospitalizations, ED visits, upper respiratory tract infections and use of antibiotics, and sinus surgeries and had an improved sense of smell.
Similar(57)
In long-term extension of the BRIGHT study, 46 RA patients (mean disease duration 10.3 years) whose DAS28-CRP was less than 2.7 by MTX plus adalimumab were randomized to a continued group or discontinued group.
patients had discontinued treatment (Group A, 97%; Group B, 95%; Group C, 99%) (Table 5).
In the group with children older than 5 years (group III), 25% wanted to continue storing their embryos, and 75% discontinued; this group was similar to group II.
In 2003 2005, TNF inhibitors were discontinued perioperatively (group A) but not during 2006 2009 (group B).
In addition, one patient in the placebo group discontinued during the parallel-group phase because of an adverse event.
Although 58, 52, and 57% of these groups discontinued (or were given rescue treatment with pioglitazone) for lack of glycemic control, 72% of those in the placebo group discontinued or required rescue treatment.
In all, 72 (43.6%) subjects in the diabetic group and 485 (34.8%) subjects in the nondiabetic group discontinued treatment prematurely; causes and their reporting rates were similar between groups.
Significantly more patients in the duloxetine 60 mg BID group than the placebo group discontinued treatment due to adverse events.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com